Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (3): 507-513.DOI: 10.19852/j.cnki.jtcm.20230214.004
Previous Articles Next Articles
Efficacy of Danggui Buxue decoction (当归补血汤) on diabetic nephropathy-induced renal fibrosis in rats and possible mechanism
ZHAO Ye1, WANG Xian1, GU Ling2, LI Zihang2, ZHU Jingtian2, WANG Wenkai2, ZHANG Liang1(
), XUE Mei2()
- 1 School of Pharmacy, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China
2 College of Traditional Chinese Medicine?College of Intergrated Chinese and Western Medicine, Nanjing University of Chinese Medicine Nanjing 210023, China
-
Received:2022-01-23Accepted:2022-05-25Online:2023-06-15Published:2023-02-14 -
Contact:Prof. ZHANG Liang, School of Pharmacy, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. zhangl_1999@njucm.edu.cn -
Supported by:Research on the Mechanism of Danggui Buxue Decoction in the Treatment of Diabetic Renal Interstitial Fibrosis Based on the Regulation of TGF-β1/Smad3 Signaling Pathway by MiRNA-27a(NZY81904085)
Cite this article
ZHAO Ye, WANG Xian, GU Ling, LI Zihang, ZHU Jingtian, WANG Wenkai, ZHANG Liang, XUE Mei. Efficacy of Danggui Buxue decoction (当归补血汤) on diabetic nephropathy-induced renal fibrosis in rats and possible mechanism[J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 507-513.
share this article
Figure 1 Effect of DBD on biological indicators related to kidney injury in GK rats A: blood creatinine; B: blood urea nitrogen; C: total cholesterol; D: triglycerides; E: low-density lipoprotein; F: high-density lipoprotein; G: 24-hour urine protein; H: renal coefficient. Con: control group; DN: model group; Gliquidone: positive drug group (gavage of benazepril hydrochloride and glitazone suspension 10 mg/kg once a day, 8 weeks); Ast: astragaloside IV group (40 mg/kg) once a day, 8 weeks; 2, 4, 8 g/kg: DBD low-dose, medium-dose, and high-dose groups, once a day for 8 weeks. Con: control group; DN: model group; Gliquidone: positive drug group; 2 g/kg: low dose group; 4 g/kg: medium dose group; 8 g/kg: high dose group; Astragaloside IV: astragaloside group. DBD: Danggui Buxue decoction; GK: Goto Kakizaki; DN: diabetic nephropathy. Data are expressed as the mean ± standard deviation (n = 10). aP<0.01, bP<0.05, cP<0.001, compared with the DN group.
Figure 1 Effect of DBD on biological indicators related to kidney injury in GK rats A: blood creatinine; B: blood urea nitrogen; C: total cholesterol; D: triglycerides; E: low-density lipoprotein; F: high-density lipoprotein; G: 24-hour urine protein; H: renal coefficient. Con: control group; DN: model group; Gliquidone: positive drug group (gavage of benazepril hydrochloride and glitazone suspension 10 mg/kg once a day, 8 weeks); Ast: astragaloside IV group (40 mg/kg) once a day, 8 weeks; 2, 4, 8 g/kg: DBD low-dose, medium-dose, and high-dose groups, once a day for 8 weeks. Con: control group; DN: model group; Gliquidone: positive drug group; 2 g/kg: low dose group; 4 g/kg: medium dose group; 8 g/kg: high dose group; Astragaloside IV: astragaloside group. DBD: Danggui Buxue decoction; GK: Goto Kakizaki; DN: diabetic nephropathy. Data are expressed as the mean ± standard deviation (n = 10). aP<0.01, bP<0.05, cP<0.001, compared with the DN group.
Figure 2 Effect of DBD on the expression of renal fibrosis-related proteins in diabetic rats A1: the expressions of α-SMA, col IV, vimentin in kidney were measured by Western blot; A2: relative density of col IV; A3: relative density of α-SMA; A4: relative density of vimentin. B1: the expressions of TGF-β1, p-smad3, smad3, p-smad5, smad5 in kidney were measured by Western blot; B2: relative density of p-smad3; B3: relative density of p-smad5; B4: relative density of TGF-β1. Con: control group; DN: model group; Gli: positive drug group (gavage of benazepril hydrochloride and gliquidone suspension 10 mg/kg once a day, 8 weeks); Ast: astragaloside IV group (40 mg/kg) once a day, 8 weeks; 2, 4, 8 g/kg: DBD low-dose, medium-dose, and high-dose groups, once a day, 8 weeks. α-SMA: α-smooth muscle actin; col IV: collagen IV; TGF-β1: transforming growth factor-β1; DBD: Danggui Buxue decoction; DN: diabetic nephropathy. Data are expressed as the mean ± standard deviation (n = 10). aP<0.05, bP<0.01, cP<0.001, compared with the DN group.
Figure 2 Effect of DBD on the expression of renal fibrosis-related proteins in diabetic rats A1: the expressions of α-SMA, col IV, vimentin in kidney were measured by Western blot; A2: relative density of col IV; A3: relative density of α-SMA; A4: relative density of vimentin. B1: the expressions of TGF-β1, p-smad3, smad3, p-smad5, smad5 in kidney were measured by Western blot; B2: relative density of p-smad3; B3: relative density of p-smad5; B4: relative density of TGF-β1. Con: control group; DN: model group; Gli: positive drug group (gavage of benazepril hydrochloride and gliquidone suspension 10 mg/kg once a day, 8 weeks); Ast: astragaloside IV group (40 mg/kg) once a day, 8 weeks; 2, 4, 8 g/kg: DBD low-dose, medium-dose, and high-dose groups, once a day, 8 weeks. α-SMA: α-smooth muscle actin; col IV: collagen IV; TGF-β1: transforming growth factor-β1; DBD: Danggui Buxue decoction; DN: diabetic nephropathy. Data are expressed as the mean ± standard deviation (n = 10). aP<0.05, bP<0.01, cP<0.001, compared with the DN group.
Figure 3 Effect of DBD on renal fibrosis in rats A: kidney immunohistochemistry staining (× 200); B: kidney Masson trichome staining (× 200); C: quantification of fibronectin-positive areas; D: quantification of collagen deposition. A1, B1: control group (rats were administered with an equal volume of saline via oral gavage once a day for 8 weeks); A2, B2: DN group (rats were administered with an equal volume of saline via oral gavage once a day for 8 weeks); A3, B3: gliquidone group (rats were administered with an equal volume of benazepril hydrochloride and gliquidone suspension 10 mg/kg via oral gavage once a day for 8 weeks); A4, B4: astregaloside IV group (rats were administered with an equal volume of astragaloside IV 40 mg/kg via oral gavage once a day for 8 weeks); A5, B5: DBD 2 g/kg group (rats were administered with an equal volume of DBD 2g/kg via oral gavage once a day for 8 weeks); A6, B6: DBD 4 g/kg group (rats were administered with an equal volume of DBD 4 g/kg via oral gavage once a day for 8 weeks); A7, B7: DBD 8 g/kg group (rats were administered with an equal volume of DBD 8 g/kg via oral gavage once a day for 8 weeks). DBD: Danggui Buxue decoction; DN: diabetic nephropathy. Data are expressed as the mean ± standard deviation (n = 10). aP<0.001, bP<0.01, cP<0.05, compared with the DN group.
Figure 3 Effect of DBD on renal fibrosis in rats A: kidney immunohistochemistry staining (× 200); B: kidney Masson trichome staining (× 200); C: quantification of fibronectin-positive areas; D: quantification of collagen deposition. A1, B1: control group (rats were administered with an equal volume of saline via oral gavage once a day for 8 weeks); A2, B2: DN group (rats were administered with an equal volume of saline via oral gavage once a day for 8 weeks); A3, B3: gliquidone group (rats were administered with an equal volume of benazepril hydrochloride and gliquidone suspension 10 mg/kg via oral gavage once a day for 8 weeks); A4, B4: astregaloside IV group (rats were administered with an equal volume of astragaloside IV 40 mg/kg via oral gavage once a day for 8 weeks); A5, B5: DBD 2 g/kg group (rats were administered with an equal volume of DBD 2g/kg via oral gavage once a day for 8 weeks); A6, B6: DBD 4 g/kg group (rats were administered with an equal volume of DBD 4 g/kg via oral gavage once a day for 8 weeks); A7, B7: DBD 8 g/kg group (rats were administered with an equal volume of DBD 8 g/kg via oral gavage once a day for 8 weeks). DBD: Danggui Buxue decoction; DN: diabetic nephropathy. Data are expressed as the mean ± standard deviation (n = 10). aP<0.001, bP<0.01, cP<0.05, compared with the DN group.
Table 1 Comparison of the levels of CRP, IL-6, TNF-α, IL-10 in different groups (pg/g, $\bar{x}±s$)
| Group | n | CRP | IL-6 | IL-10 | TNF-α |
|---|---|---|---|---|---|
| Con | 10 | 1.00±0.19 | 1.00±0.21 | 1.00±0.11 | 1.00±0.14 |
| DN | 10 | 1.61±0.22 | 1.76±0.20 | 0.59±0.15 | 1.64±0.16 |
| Gliquidone | 10 | 1.20±0.16a | 1.13±0.20b | 0.99±0.16b | 1.06±0.16b |
| Ast IV | 10 | 1.16±0.14a | 1.47±0.17 | 0.82±0.13a | 1.34±0.12a |
| DBD 2 g/kg | 10 | 1.45±0.22 | 1.55±0.23 | 0.70±0.14 | 1.49±0.17 |
| DBD 4 g/kg | 10 | 1.29±0.22 | 1.49±0.18 | 0.76±0.13a | 1.39±0.18 |
| DBD 8 g/kg | 10 | 1.16±0.16a | 1.35±0.19a | 0.87±0.16a | 1.20±0.21a |
Table 1 Comparison of the levels of CRP, IL-6, TNF-α, IL-10 in different groups (pg/g, $\bar{x}±s$)
| Group | n | CRP | IL-6 | IL-10 | TNF-α |
|---|---|---|---|---|---|
| Con | 10 | 1.00±0.19 | 1.00±0.21 | 1.00±0.11 | 1.00±0.14 |
| DN | 10 | 1.61±0.22 | 1.76±0.20 | 0.59±0.15 | 1.64±0.16 |
| Gliquidone | 10 | 1.20±0.16a | 1.13±0.20b | 0.99±0.16b | 1.06±0.16b |
| Ast IV | 10 | 1.16±0.14a | 1.47±0.17 | 0.82±0.13a | 1.34±0.12a |
| DBD 2 g/kg | 10 | 1.45±0.22 | 1.55±0.23 | 0.70±0.14 | 1.49±0.17 |
| DBD 4 g/kg | 10 | 1.29±0.22 | 1.49±0.18 | 0.76±0.13a | 1.39±0.18 |
| DBD 8 g/kg | 10 | 1.16±0.16a | 1.35±0.19a | 0.87±0.16a | 1.20±0.21a |
| [1] |
Avogaro A, Fadini GP. Microvascular complications in diabetes: a growing concern for cardiologists. Int J Cardiol 2019; 291: 29-35.
DOI PMID |
| [2] |
Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis 2018; 71: 884-95.
DOI PMID |
| [3] |
Chen Q, Zhu A, Wang J, et al. Comparative analysis of diabetic nephropathy and non-diabetic nephropathy disease. Saudi J Biol Sci 2017; 24: 1815-17.
DOI PMID |
| [4] | Yang S, Abdulla R, Lu C, et al. Inhibition of microRNA-376b protects against renal interstitial fibrosis via inducing macrophage autophagy by upregulating atg 5 in mice with chronic kidney disease. Kidney Blood Press Res 2018; 43: 1749-64. |
| [5] |
Lan HY. Transforming growth factor-β/Smad signalling in diabetic nephropathy. Clin Exp Pharmacol Physiol 2012; 39: 731-8.
DOI URL |
| [6] |
Sun X, Huang K, Haiming X, et al. Connexin 43 prevents the progression of diabetic renal tubulointerstitial fibrosis by regulating the SIRT1-HIF-1α signaling pathway. Clin Sci (Lond) 2020; 134: 1573-92.
DOI PMID |
| [7] |
Das R, Xu S, Quan X, et al. Upregulation of mitochondrial Nox4 mediates TGF-β-induced apoptosis in cultured mouse podocytes. Am J Physiol Renal Physiol 2014; 306: F155-67.
DOI URL |
| [8] | Frangogiannis N. Transforming growth factor-β in tissue fibrosis. J Exp Med 2020; 217: e20190103. |
| [9] |
Loeffler I, Liebisch M, Allert S, et al. FSP1-specific SMAD2 knockout in renal tubular, endothelial, and interstitial cells reduces fibrosis and epithelial-to-mesenchymal transition in murine STZ-induced diabetic nephropathy. Cell Tissue Res 2018; 372: 115-33.
DOI PMID |
| [10] |
Lin PL, Li ZC, Xie RF, et al. Compatibility study of Danggui Buxue Tang on chemical ingredients, angiogenesis and endothelial function. Sci Rep 2017; 7: 45111.
DOI |
| [11] | Zhang R, Han X, Huang T, et al. Danggui buxue tang inhibited mesangial cell proliferation and extracellular matrix accumulation through GAS5/NF-κB pathway. Biosci Rep 2019; 39: BSR20181740. |
| [12] |
Zhang H, Chen S, Deng X, et al. Danggui-Buxue-Tang decoction has an anti-inflammatory effect in diabetic atherosclerosis rat model. Diabetes Res Clin Pract 2006; 74: 194-6.
DOI URL |
| [13] | Chen X. Danggui Buxue Tang attenuates tubulointerstitial fibrosis via suppressing NLRP3 inflammasome in a rat model of unilateral ureteral obstruction. Biomed Res Int 2016; 2016: 9368483. |
| [14] | Huang WJ, Fu Q, Xiao YH, et al. Effect of ufengtongluo decoction on PI3K/Akt signaling pathway in the kidney of Type 2 diabetes mellitus rat (GK rat) with diabetic nephropathy. Evid Based Complement Alternat Med 2018; 2018: 8421979. |
| [15] |
Kubota M, Watanabe R, Kabasawa H, et al. Rice protein ameliorates the progression of diabetic nephropathy in Goto-Kakizaki rats with high-sucrose feeding. Br J Nutr 2013; 110: 1211-9.
DOI URL |
| [16] |
Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 2017; 317: 2515-23.
DOI PMID |
| [17] |
Holman N, Young B, Gadsby R. Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK. Diabet Med 2015; 32: 1119-20.
DOI URL |
| [18] |
Bruno G, Runzo C, Cavallo-Perin P, et al. Piedmont study group for diabetes epidemiology. Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy. Diabetes Care 2005; 28: 2613-9.
DOI PMID |
| [19] | Pang B, Yu XT, Zhou Q, et al. Effect of rhizoma coptidis (Huang Lian) on treating diabetes mellitus. Evid Based Complement Alternat Med 2015; 2015: 921416. |
| [20] |
Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes 2017; 9: 434-49.
DOI PMID |
| [21] |
Wang J, Ma Q, Li Y, et al. Research progress on traditional chinese medicine syndromes of diabetes mellitus. Biomed Pharmacother 2020; 121: 109565.
DOI PMID |
| [22] |
Xue M, Bian Y, Liu YL, et al. Danggui Buxue decoction ameliorates lipid metabolic defects involved in the initiation of diabetic atherosclerosis; identification of active compounds. J Tradit Chin Med 2020; 40: 414-21.
DOI PMID |
| [23] |
Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 30: 49-59.
DOI URL |
| [24] |
Zhang S, Xu L, Liang R, et al. Baicalin suppresses renal fibrosis through microRNA-124/TLR4/NF-κB axis in streptozotocin-induced diabetic nephropathy mice and high glucose-treated human proximal tubule epithelial cells. J Physiol Biochem 76: 407-16.
DOI |
| [25] |
Pourghasem M, Shafi H, Babazadeh Z. Histological changes of kidney in diabetic nephropathy. Caspian J Intern Med 2015; 6: 120-7.
PMID |
| [26] | Lü J, Zhao Z, Chen Y, et al. The Chinese herbal decoction Danggui Buxue Tang inhibits angiogenesis in a rat model of liver fibrosis. Evid Based Complement Alternat Med 2012; 2012: 284963. |
| [27] |
Feng H, Zhu X, Tang Y, et al. Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP 3 inflammasome‑mediated inflammation. Int J Mol Med 2021; 48: 164.
DOI URL |
| [28] |
Zhang J, Liu J, Qin X. Advances in early biomarkers of diabetic nephropathy. Rev Assoc Med Bras (1992) 2018; 64: 85-92.
DOI URL |
| [29] |
Nickel J, Ten Dijke P, Mueller TD. TGF-β family co-receptor function and signaling. Acta Biochim Biophys Sin (Shanghai) 2018; 50: 12-36.
DOI URL |
| [30] |
Higgins SP, Tang Y, Higgins CE, et al. TGF-β1/p53 signaling in renal fibrogenesis. Cell Signal 2018; 43: 1-10.
DOI PMID |
| [31] |
Ji X, Cao J, Zhang L, et al. Kaempferol protects renal fibrosis through activating the BMP-7-Smad1/5 signaling pathway. Biol Pharm Bull 2020; 43: 533-9.
DOI PMID |
| [32] | Xu BH, Sheng J, You YK, et al. Deletion of Smad 3 prevents renal fibrosis and inflammation in type 2 diabetic nephropathy. Metabolism 2020; 103: 154013. |
| [33] | Ma TT, Meng XM. TGF-β/Smad and renal fibrosis. Adv Exp Med Biol 2019; 1165: 347-64. |
| [34] | Xue Q, Jiang H, Wang J, et al. LASP1 induces epithelial-mesenchymal transition in lung cancer through the TGF-β1/Smad/Snail pathway. Can Respir J 2021; 2021: 5277409. |
| [35] | Zheng W, Qian C, Xu F, et al. Fuxin granules ameliorate diabetic nephropathy in db/db mice through TGF-β1/Smad and VEGF/VEGFR2 signaling pathways. Biomed Pharmacother 2021; 141: 111806. |
| [36] | Niu H, Miao X, Zhan X, et al. Tiaoshen Tongluo attenuates fibrosis by modulating the TGF-β1/Smad pathway in endometrial stromal cells and a rat model of intrauterine adhesion. Evid Based Complement Alternat Med 2021; 2021: 6675329. |
| [37] |
Fan Z, Wang Y, Xu X, et al. Inhibitor of bruton's tyrosine kinases, PCI-32765, decreases pro-inflammatory mediators' production in high glucose-induced macrophages. Int Immunopharmacol 2018; 58: 145-53.
DOI PMID |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
